1. Home
  2. INTS vs THH Comparison

INTS vs THH Comparison

Compare INTS & THH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$3.37

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Logo TryHard Holdings Limited Ordinary Shares

THH

TryHard Holdings Limited Ordinary Shares

HOLD

Current Price

$1.55

Market Cap

11.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTS
THH
Founded
2012
2013
Country
United States
Japan
Employees
N/A
116
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.7M
11.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
INTS
THH
Price
$3.37
$1.55
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $38.00
N/A
AVG Volume (30 Days)
11.2K
★ 75.8K
Earning Date
05-07-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$305.05
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.19
52 Week High
$8.06
$56.26

Technical Indicators

Market Signals
Indicator
INTS
THH
Relative Strength Index (RSI) 33.38 47.97
Support Level $3.51 $1.37
Resistance Level $4.30 $1.87
Average True Range (ATR) 0.21 0.21
MACD -0.03 -0.02
Stochastic Oscillator 6.61 16.67

Price Performance

Historical Comparison
INTS
THH

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

About THH TryHard Holdings Limited Ordinary Shares

Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.

Share on Social Networks: